Death of Good Times? Hardly

I guess when you are Sequoia, you can hold a big public media-attended meeting where you display a faux tombstone ominously announcing the death of the Good Times. My approach has to be a little bit different. The investments that I am making, both at Accelerator and OVP Venture Partners, are generally years from accessing public markets or being acquired, so current market conditions are not high on my list of considerations. Great technologies emerge in both bull and bear markets, and if I am sitting on the sidelines now that leaves a hole in my portfolio 3-5 years from now. What if that is the midst of the decade’s greatest bull market? Or not? I have no way to forecast that. So from an investment side, I have to treat this as pretty much business as usual.

On the cash conservation side, we preach that gospel in any market. To say that we would pay more attention to it now is to say that we are more careless with cash at other times. That is not the case – cash is king in any market, and my investors expect me to behave that way at all times.

Author: Carl Weissman

Carl Weissman is senior advisor and former CEO and chairman at Accelerator, a joint investment vehicle backed by a syndicate of venture capital firms. Accelerator invests in and actively manages emerging biotechnology companies. Carl was also previously a Venture Partner at MPM Capital. While at MPM, he served as President and CEO of Centagenetix, a human genetics company in Cambridge, MA. Carl led the 2003 merger of Centagenetix with Elixir Pharmaceuticals, catalyzing a $40M Series B financing in the combined company. Prior to joining MPM, he spent six years at Prolinx, Inc., where he held a number of positions, culminating as the head of both Finance and Business Development. Carl serves on the board of the WBBA and is Vice President of the Board of Teens in Public Service.